H. Lundbeck

Symptomatic and Functional Response to Brexpiprazole Treatment in Patients With Acute Schizophrenia by Age

Introduction: The efficacy and safety of brexpiprazole in the treatment of schizophrenia have been demonstrated in short- and long-term studies. This post-hoc analysis assessed the propor...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Peter Zhang , PhD;

Erin MacKenzie , PhD;

Francois Therrien , PharmD;

03/01/2019

The Impact of Second-Generation Antipsychotic Medication Side-Effects on Functioning From a Schizophrenia Patient Perspective: a Cross-Sectional, Observational, Patient Centered, Web Survey Study

Background: Second-generation antipsychotics (SGAs) are associated with well-known side effects (SEs). We aimed to gain a patients’ perspective on how specific SEs impact daily functionin...

William Lenderking , PhD;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Huda Shalhoub , PhD;

Ann Hartry , PhD;

Mallik Greene , PhD, DBA;

Laetitia Bouerat Duvold , PhD;

Owen Cooper , MSc;

Leah Kleinman , DrPH;

Randall Bender , PhD;

Rajiv Tandon , MD;

03/01/2019

Effect of Adjunctive Brexpiprazole on Sexual Functioning in MDD According to Concomitant Antidepressant: Post Hoc Analysis of Four Short-Term Studies

Background: We aimed to determine the effects of adjunctive brexpiprazole on sexual functioning in adults with major depressive disorder (MDD), according to antidepressant treatment (ADT)...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Malaak Brubaker , PhD;

Peter Zhang , PhD;

Mary Hobart , PhD;

11/22/2019

The Impact of Second-Generation Antipsychotic Side-Effects on Functioning From a Schizophrenia Patient Perspective: A Global Patient Centered Survey

Background: The impact of side effects (SEs) of second-generation antipsychotics (SGAs) on patients’ physical and emotional functioning and overall quality of life (QoL) is insufficiently...

Mallik Greene , PhD, DBA;

Laetitia Bouerat Duvold , PhD;

Catherine Weiss , PhD;

William Lenderking , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Huda Shalhoub , PhD;

Carla Dias-Barbosa , MSc;

Jun Chen , MS, MSc;

Andrea Schulz , MA;

Ann Hartry , PhD;

11/22/2019

Exploring Patient Experiences Taking Adjunctive Brexpiprazole for Major Depressive Disorder (MDD): Post-hoc Analysis of Exit Interview Data

Background: The efficacy and safety of adjunctive brexpiprazole, a serotonin–dopamine activity modulator, has been demonstrated in clinical studies in adults with MDD and inadequate respo...

Michelle Brown , PhD;

Catherine Gupta , PhD;

Dana DiBenedetti , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Roger McIntyre , MD, FRCPC;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

11/22/2019